Please login to the form below

Not currently logged in
Email:
Password:

Vibativ is granted marketing authorisation

European marketing authorisation has been granted for Vibativ, a once-daily injection to treat hospital acquired nosocomial pneumonia

Astellas Pharma Europe and Theravance have announced that the European Medicines Agency (EMA) has granted marketing authorisation for Vibativ (telavancin hydrochloride), used to treat hospital-acquired nosocomial pneumonia via a once-daily bactericidal injection.

The authorisation follows a positive opinion from the Committee for Human Medicinal Products (CHMP) and grants the treatment of adults in Europe with nosocomial pneumonia including ventilator-associated pneumonia, known or suspected to be caused by MRSA. It has been granted for when other alternatives are not suitable.

Vibativ is a once-daily injectable lipoglycopeptide antibacterial agent that has a dual mechanism of action against Gram-positive bacteria, including resistant pathogens such as methicillin-resistant Staphylococcus aureus (MRSA).

Vibativ provides an "effective hospital antibiotic option for patients with hospital-acquired pneumonia caused by MRSA" stated Ken Jones, president and CEO of Astellas Pharma Europe.

15th September 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics